Future developments in the selectivity of anticancer agents: drug delivery and molecular target strategies.
In the past, our limited understanding of the processes involved in the initiation and growth of cancer hindered our ability to effectively treat most human malignancies and therapies were often associated with significant toxic side effects as well as re-emergence of disease. The development of drug delivery systems such as liposomes has improved the specificity of various conventional anticancer agents by enhancing drug accumulation in tumors while often decreasing exposure to susceptible healthy tissues. More recently, the identification of a wide range of genes and corresponding protein products that are altered in various human cancers has revealed new molecular targets for cancer therapy that may provide improved selectivity for tumor cells over traditional cytotoxic agents. This review discusses how advances in the sophistication of liposomal delivery systems may open new opportunities for combining novel molecular targeting strategies with pharmacological targeting via liposomes to optimize the therapy of many human malignancies.
Mayer
L D
LD
Department of Advanced Therapeutics, BC Cancer Agency, Vancouver, Canada. lmayer@bccancer.bc.ca
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004337:Drug Carriers; D016503:Drug Delivery Systems; D015316:Genetic Therapy; D006801:Humans; D008081:Liposomes; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D009374:Neoplasms, Experimental / Q000188:drug therapy* / Q000235:genetics*
D000970:Antineoplastic Agents; D004337:Drug Carriers; D008081:Liposomes